Mirvetuximab Soravtansine vs Chemotherapy in Patients With Platinum-Resistant Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase III, Randomized Trial of Mirvetuximab Soravtansine Versus Chemotherapy in Patients With Platinum-Resistant Ovarian Cancer: Primary Analysis of FORWARD I
Ann. Oncol 2021 Mar 02;[EPub Ahead of Print], KN Moore, AM Oza, N Colombo, A Oaknin, G Scambia, D Lorusso, GE Konecny, S Banerjee, CG Murphy, JL Tanyi, H Hirte, JA Konner, PC Lim, M Prasad-Hayes, BJ Monk, P Pautier, J Wang, A Berkenblit, I Vergote, MJ BirrerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.